A core product for Type 2 diabetes is expected to commercially launch in mainland China by the end of this year, subject to regulatory approval; CICC led the transaction.
CICC is looking to strengthen ties between China and the Gulf region; meanwhile, a former MD at Standard Chartered, Kapil Jobanputra, has become managing partner of real asset firm Elaeo Partners.
The dual listing will help keep momentum in Hong Kong's equity markets, with the majority of the $4.5bn proceeds raised by the Shenzhen based global EV player set to help build a factory in Hungary; a greenshoe option takes the raising to $5.2bn.